Table 1. The main characteristics of Chinese TM patients along with the main results of the study.
| Patients(n = 201) | |
| Male [n (%)] | 125(62.2) |
| Ethnicity | |
| Han | 161 |
| Other | 40 |
| Median age (range),years | 9(4–25) |
| Age group, years | |
| <6 [n (%)] | 14(7) |
| 6–<10 [n (%)] | 89(44.2) |
| 10–<15 [n (%)] | 79(39.3) |
| 15–<20 [n (%)] | 14(7) |
| 20–<25 [n (%)] | 5(2.5) |
| Previous chelation therapy, [n (%)] | |
| DFO | 42(20.9) |
| DFP | 25(12.4) |
| DFO+DFPa | 95(47.3) |
| DFX | 8(4) |
| DFO+DFXb | 20(9.9) |
| None | 11(5.5) |
| Mean ± SD number of transfusions | 116.3±91.4 |
| Median SF ng/mL (range) | 4536(524.7–23,640) |
| SF category [n (%)] | |
| <2500 ng/mL | 36(17.9) |
| ≥2500 ng/mL | 165(82.1) |
| cardiac T2*, ms | 25.5±12.5 |
| T2* category [n (%)] | |
| <10 ms | 26(12.9) |
| 10–20 ms | 42(20.9) |
| >20 ms | 133(66.2) |
| LVEF, [%] | 64.8±5.6 |
| LVEF category [n] | 175 |
| <56% [n (%)] | 6(3.4) |
| ≥56% [n (%)] | 169(96.6) |
DFO,deferoxamine; DFP, deferiprone; DFX, deferasirox; SD, standard deviation; SF, serum ferritin; LVEF, left ventricular ejection fraction.
a: patients received both DFO and DFP as prior chelation therapies, but these may not have been in combination.
b: patients received both DFO and deferasirox as prior chelation therapies, but these may not have been in combination.